DDIT3 and neoplasm: In a phase I trial, ONC201 triggered the ISR along with induction of CHOP and TNFRSF10B in an ibrutinib-refractory mantle cell lymphoma patient following 16 days of treatment, which aligned with therapeutic exposure to ONC201 and target engagement in the tumor (15).